Fate Therapeutics Initiates Potentially Registrational RECLAIM-LN Clinical Trial of FT819 for the Treatment of Lupus Nephritis
Fate Therapeutics initiated the RECLAIM-LN Phase 2 potentially registrational trial of FT819 for lupus nephritis, dosing the first patient in an outpatient setting. The study aims to enroll approximately 53 patients refractory to standard therapies, with full enrollment anticipated by the first half of 2028.
Key figures
- Drug Name
- FT819
- Phase Of Trial
- Phase 2
- Dose
- 900 million-cell
- Patient count
- approximately 53
- Enrollment completion
- 1H2028
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.